{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-22-000163","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.531082+00:00","generated_at":"2026-06-22T04:59:13.876660+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NeoGenomics appoints David Perez to board, Warren Stone as clinical services president","bullets":["David B. Perez appointed to Board effective Nov 3, 2022; term until 2023 annual meeting.","Warren Stone appointed President, Clinical Services Division effective Nov 21, 2022, replacing Dr. David Sholehvar.","Stone's compensation: $525K base, 50% target bonus, $1M annual equity, $350K sign-on cash, $2M sign-on equity, $250K relocation.","Perez is former Terumo BCT CEO; brings 40 years of global executive leadership experience in medical devices and healthcare."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-22-000163","json":"https://secwatch.observer/filing/0001077183-22-000163.json","markdown":"https://secwatch.observer/filing/0001077183-22-000163.md","text":"https://secwatch.observer/filing/0001077183-22-000163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/neo-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:59:13.876660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91d0e316d5","claim":"David B. Perez was appointed as Director at NEOGENOMICS INC.","evidence_excerpt":"Effective November 3, 2022, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), appointed David B. Perez to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9b3ee880f5","claim":"Dr. David Sholehvar departed as President, Clinical Services Division at NEOGENOMICS INC.","evidence_excerpt":"The Company's former President, Clinical Services Division, Dr. David Sholehvar’s last day at the Company was November 4, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President, Clinical Services Division"}],"fact_type":"executive_change"},{"claim_id":"d6db27ba1e","claim":"Warren Stone was appointed as President, Clinical Services Division at NEOGENOMICS INC.","evidence_excerpt":"On November 2, 2022, the Company appointed Warren Stone, age 50, President, Clinical Services Division of the Company, effective November 21, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Clinical Services Division"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}